Evaluating the Effects of Testosterone Replacement Treatment on Lipid and Glycemic Profiles of Male Patients with Hypogonadism
Main Article Content
Abstract
Objective: The objective of this study was to determine the effect of Testosterone Replacement Treatment (TRT) on lipid and glycemic profiles of hypogonadal men in Pakistani population.
Methodology: This was an observational retrospective study carried out in MTI Lady Reading Hospital, Peshawar, from August 2022 to August 2023. All the cases of male hypogonadism, either with type 2 diabetes mellitus (T2DM) or in a non-diabetic status, who had received testosterone replacement treatment were included in the study. Repeated measures Anova was used to see to see any difference in baseline, 6 months and 12 months’ post treatment with testosterone of Total Cholesterol (TC), LDL cholesterol, HDL cholesterol, triglycerides HbA1C, and PSA.
Results:
Data of (n= 57) hypogonadal men who received TRT was available. Thirty-four (59.6 %) patients were diabetic and 23 (40.4 %) patients were non diabetic. Mean and standard deviation for age was 51.2 ± 7.3 years. There was a significant reduction of TC, LDL cholesterol, triglycerides and HbA1C with TRT. The change in HDL cholesterol was not significant.
Conclusion: TRT improves TC, LDL cholesterol and triglycerides in patients with hypogonadism of both diabetic and euglycemic status. It also significantly improves glycemic profile in patients with T2DM.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
1. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89(12):5920-6. DOI: 10.1210/jc.2003-031719.
2. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92(11):4241-7. DOI: 10.1210/jc.2007-1245.
3. Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012;97(5):1508-16. DOI: 10.1210/jc.2011-2513.
4. Haring R, Ittermann T, Völzke H, Krebs A, Zygmunt M, Felix SB, et al. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the Study of Health in Pomerania. Aging Male 2010;13(4):247-57. DOI: 10.3109/13685538.2010.487553.
5. Ali A, Naeem A, Naseer L, Naeem N, Waheed S, Mastoor M. Frequency and correlation of hypogonadism in men with type 2 diabetes. Pak J Med Health Sci 2022;16(10):393-5.
6. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30(6):726-33. DOI: 10.2164/jandrol.108.007005.
7. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89(11):5462-8. DOI: 10.1210/jc.2004-0804.
8. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34(4):828-37. DOI: 10.2337/dc10-1233.
9. Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care 2016;39(1):82-91. DOI: 10.2337/dc15-1518.
10. Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care 2014;37(8):2098-107. DOI: 10.2337/dc13-2845.
11. Grossmann M, Hoermann R, Wittert G, Yeap BB. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Clin Endocrinol (Oxf) 2015;83(3):344-51. DOI: 10.1111/cen.12638.
12. Corona G, Vena W, Pizzocaro A, Vignozzi L, Sforza A, Maggi M. Testosterone therapy in diabetes and pre-diabetes. Andrology 2023;11(2):204-14. DOI: 10.1111/andr.13357.
13. Groti K, Žuran I, Antonič B, Foršnarič L, Pfeifer M. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male 2018;21(3):158-69. DOI: 10.1080/13685538.2017.1342489.
14. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63(3):280-93. DOI: 10.1111/j.1365-2265.2005.02339.x.
15. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2011;34(6 Pt 1):528-40. DOI: 10.1111/j.1365-2605.2010.01117.x.
16. Maggio M, Snyder PJ, De Vita F, Ceda GP, Milaneschi Y, Luci M, et al. Effects of transdermal testosterone treatment on inflammatory markers in elderly men. Endocr Pract 2014;20(11):1170-7. DOI: 10.4158/EP14018.OR.
17. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Lessons from the Testosterone Trials. Endocr Rev 2018;39(3):369-86. DOI: 10.1210/er.2017-00234.
18. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154(6):899-906. DOI: 10.1530/eje.1.02166.
19. Saad F, Haider KS, Haider A. Long-term testosterone therapy improves lipid profile in men with functional hypogonadism and overweight or obesity: 12-year observational data from a controlled registry study in a urological setting. Endocr Abstr 2021;73:AEP232. DOI: 10.1530/endoabs.73.AEP232.
20. Yassin A, Haider A, Haider KS, Doros G, Saad F. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care 2019;42(6):1104-11. DOI: 10.2337/dc18-2205.
21. Gopal RA, Bothra N, Acharya SV, Ganesh HK, Bandgar TR, Menon PS, et al. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract 2010;16(4):570-6. DOI: 10.4158/EP09176.OR.
22. Kumari K, Kumar R, Memon A, Kumari B, Tehrim M, Kumari P, et al. Treatment with testosterone therapy in type 2 diabetic hypogonadal adult males: a systematic review and meta-analysis. Clin Pract 2023;13(2):454-69. DOI: 10.3390/clinpract13020041.
23. Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther 2017;22(5):414-33. DOI: 10.1177/1074248417691134.
24. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018;103(5):1715-44. DOI: 10.1210/jc.2018-00229.